Furthermore, addition of anti-PD-L1 to tumor bearing mice significantly enhanced the anti-OVA T cell response approximately threefold in both tumor and spleen, confirming that anti-PD-L1 ICI was able to expand anti-HCCTAA CD8+ T cell responses in vivo (Figs. 4A–B). This evidence concerns the gene CD8A and neoplasm.